Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

Dose-ranging Study of Rifaximin Soluble Solid Dispersion (SSD) Tablets for the Prevention of Complications of Early Decompensated Liver Cirrhosis

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
Valeant Pharmaceuticals International, Inc.
ClinicalTrials.gov Identifier:
NCT01904409
First received: July 17, 2013
Last updated: March 2, 2016
Last verified: March 2016
No Study Results Posted on ClinicalTrials.gov for this Study
  Study Status: This study has been completed.
  Study Completion Date: July 2015
  Primary Completion Date: June 2015 (Final data collection date for primary outcome measure)